What is Arthrosamid for the hip joint

Arthrosamid is a 2.5% cross-linked polyacrylamide hydrogel injection, made up of 97.5% water, used to ease osteoarthritis symptoms rather than to repair damaged cartilage in the hip joint. In plain terms, it is a hydrogel placed inside the joint, and some UK clinics now offer it as an ultrasound-guided hip injection for hip osteoarthritis.

The key regulatory point is narrower. Official Arthrosamid materials indexed in 2023 describe it for symptomatic treatment of adult patients with knee osteoarthritis, so use in the hip is off-label. In UK practice, off-label does not automatically mean improper or experimental; it means a treatment is being used outside its formal licence when a clinician believes there is a sound reason to do so. The practical consequence is that the formal approval and the stronger published evidence sit with the knee, not the hip.

For patients weighing up a hip injection in 2025, the sensible conclusion is cautious rather than alarmist: Arthrosamid is a real option in practice, but hip-specific evidence remains limited, so it is better seen as one part of a wider hip pain pathway than as a stand-alone answer. Lincolnshire Hip reflects that broader approach by listing Arthrosamid among its injection options alongside other routes through hip care.

What hip-specific evidence actually shows

By 2025, the honest position is that published human evidence for Arthrosamid is centred on osteoarthritis in the knee, not the hip joint. No robust peer-reviewed hip trial was identified here, so several practical questions remain open in the hip: how much symptom relief is likely, how long any benefit lasts, which stage of hip osteoarthritis responds best, and what the true complication pattern looks like in a deeper joint.

That leaves Arthrosamid in the hip in a cautious middle ground. It is not simply a theoretical idea, because UK clinics are already offering ultrasound-guided hip injections, and Lincolnshire Hip includes Arthrosamid within its hip injection pathway in Grantham and Sleaford. Even so, it currently sits closer to a private off-label option with limited direct hip evidence than to an established, guideline-backed treatment for hip osteoarthritis.

Where figures such as 24-month or 5-year improvement are quoted, they come from knee cohorts. Those studies may offer useful context about durability and safety, but they do not prove that the same effect size, candidate profile, or risk pattern applies inside the hip joint.

Who may be considered for hip Arthrosamid

In practice, the people most likely to raise Arthrosamid in a 2025 hip clinic are those with osteoarthritis confirmed on assessment, whose pain pattern looks as though it is coming from the hip joint itself. The conversation is usually about symptom control, not cartilage repair: persistent groin or deep joint pain, stiffness, and day-to-day limits with walking, stairs or sleep, in someone who wants a non-surgical option for now or is not currently suited to hip replacement.

That is still a discussion rather than a checklist. The nearest selection clues come from a 24-month knee cohort, where lower osteoarthritis grade and the absence of diabetes were linked with better odds of meaningful improvement, while more advanced disease was associated with later joint replacement; those signals may not translate directly to the hip. At Lincolnshire Hip, with local access in Grantham and Sleaford, Arthrosamid therefore sits as one possible option after the assessment has clarified the pain source, imaging findings, functional limits, and whether the aim is to defer surgery rather than move straight to it.

How Arthrosamid compares with other hip injections

For hip osteoarthritis, the clearest comparison starts with corticosteroid. A 2022 review of intra-articular hip injections found that corticosteroid can provide pain relief in the hip joint, so it remains the better-established option when the aim is short-term symptom control. The same review advises against repeated injections and recommends leaving more than 3 months before hip arthroplasty. Hyaluronic acid sits in a different category: some centres use it, but the review notes that national guidelines do not favour HA for hip osteoarthritis, and it is best understood as symptom management rather than repair of damaged hip cartilage.

The more useful comparison with Arthrosamid is by treatment goal, not by novelty. PRP and other biologic-style injections occupy a less settled area in the hip: the 2022 review describes PRP, mesenchymal stem cells and BMAC as options with conflicting evidence, so they are not straightforward one-for-one substitutes. Lincolnshire Hip describes “two paths through hip pain” and lists Arthrosamid, ChondroFiller and PRP among its injection-based options. In that setting, Arthrosamid fits most sensibly as one comparison option within a broader hip-joint decision, not as the automatic next step after diagnosis.

What risks matter in the hip joint

The key safety issue is that Arthrosamid is not a temporary filler. Published product and study material describe a 2.5% polyacrylamide hydrogel that is non-absorbable and non-biodegradable, so it is designed to remain in the hip joint rather than wear off in the way a short-acting injection might. That does not prove harm, but it does change the trade-off: if symptom relief is modest, or if the joint reacts badly, the problem may be harder to manage than after a treatment that simply fades with time.

Short-term UK data published in 2025 give a useful warning sign, even though they come from osteoarthritis treatment outside the hip. In a series of 204 patients, two re-attended with important inflammatory problems: one had a joint aspiration at 3 weeks, and one had a severe soft-tissue reaction that required washout and debridement; infection aspirates were negative in both cases. Because the published Arthrosamid literature is still centred on knee practice rather than the hip joint, no firm hip-specific rate can be given for inflammation, migration, or difficult revision. For Lincolnshire Hip, that makes safety a consent discussion based on known trade-offs and genuine uncertainty, not on false reassurance or alarm.

When a Lincolnshire Hip assessment makes sense

Taken together, the realistic verdict in 2025 is fairly narrow. Arthrosamid appears to be a genuine hip joint option in some UK private practice, but not a routine first-choice injection for hip osteoarthritis. The reason is practical: official Arthrosamid materials are for knee osteoarthritis, the published outcome studies most often cited are still knee studies, and in hip osteoarthritis the better-established injection evidence remains corticosteroid for short-term relief rather than longer-term hydrogel use.

That is why a focused hip assessment matters most when pain has persisted and the next step is unclear: confirming that the hip joint is truly the pain driver, reviewing what evidence exists for each option, and deciding whether Arthrosamid’s uncertainty is an acceptable trade-off in a non-surgical pathway. At Lincolnshire Hip, that discussion sits within a consultant-led hip service with local access in Sleaford and Grantham, with surgery in London if that later becomes relevant.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

1. [1] Comparative efficacy of polyacrylamide hydrogel versus hyaluronic acid and corticosteroids in knee osteoarthritis: A retrospective cohort study. (2025). https://doi.org/10.1097/MD.0000000000044655 https://doi.org/10.1097/MD.0000000000044655